PDC*line Pharma Opens Last Cohort of PDC-LUNG-101 Clinical Trial
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces that the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 phase I/II clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).
PDC*lung01 is a cell suspension of a mix, in the same proportion, of seven active agents – made of irradiated human plasmacytoïd dendritic cells (PDC*line), loaded separately with a distinct synthetic human leukocyte antigen serotype-restricted peptide – (HLA-A*02:01), encoded by a tumor antigen. PDC*line is a potent professional antigen-presenting cell that is able to prime and boost the antitumor cytotoxic CD8+ T-cells in the patient’s immune system.
The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients. PDC*lung01 will be administered to 62 evaluable HLA-A*02:01 positive NSCLC patients at two dose levels in two different settings: as a single agent to adjuvant patients (A1: Low Dose, A2: High Dose), or added to standard of care anti-PD-1 monotherapy to patients with first-line stage IV (metastatic) NSCLC disease (B1: Low Dose, B2: High Dose).
Following the completion of the first three cohorts (A1, A2 and B1), the Data and Safety Monitoring Board (DSMB) assessed all safety parameters. As no dose-limiting toxicity or other safety signals were observed, it allowed the opening of the last cohort, B2.
This cohort of 42 evaluable patients will assess PDC*lung01 at ‘High Dose’ added to pembrolizumab in monotherapy in a first line Stage IV setting.
The first patient dosed in the B2 cohort is under the supervision of Dr Kristof Cuppens, medical oncologist at the Jessa Ziekenhuis Hospital in Hasselt (Belgium). Currently, there are clinical sites open in France, Belgium and Germany.
“This is a very interesting trial with PDC*lung01 vaccine, especially thanks to the potential to administer it in combination with anti-PD1 immunotherapy. Early data from the first three cohorts show a very mild safety profile and good patient acceptance,” said Prof Vansteenkiste, head of clinic – respiratory oncology unit and trial unit – department of respiratory diseases (KU Leuven / Belgium) and chair of the DSMB.
“We are delighted to have achieved this new milestone in our NSCLC clinical trial, which is progressing well – despite the Covid-19 pandemic. We look forward to completing the B2 cohort, in order to assess the preliminary clinical activity of our vaccine in association with anti-PD1 immunotherapy in the target NSCLC population,” said Eric Halioua, CEO of PDC*line Pharma.
“I would like to thank both the investigators and patients for their continued participation in the study. We are encouraged by the favorable safety profile, also in combination with anti-PD1. We are looking forward to opening new clinical centers in The Netherlands and Poland; ensuring a continued smooth enrolment for this target trial population,” said Dr. Channa Debruyne, medical director of PDC*line Pharma.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more